The 2025 America’s Best-in-State Hospitals ranking by Newsweek and Statista recognized Texas’s top hospitals, with Houston Methodist Hospital leading the list, followed by UT Southwestern and Baylor University Medical Center as the second and third best hospitals in the state. Medical City was ranked the sixth best hospital in the state. The ranking, which identifies the best 700 hospitals in the nation, is based on hospital quality metrics, a survey of medical professionals, patient experience, and PROMs (patient-reported outcome measures) implementation.
The Anne Burnett Marion School of Medicine at TCU and UT Arlington have launched a joint M.D.-Ph.D. program in biomedical engineering, aiming to produce physician-scientists skilled in both clinical practice and biomedical research. The first cohort will be admitted in the 2024 M.D. admissions cycle, starting in July 2025. The program merges TCU’s innovative medical education with UTA’s bioengineering research strengths, offering students rigorous training and research opportunities. Leaders from both institutions emphasize that graduates will be prepared to address complex biomedical challenges, advancing health care innovation and bridging traditional medicine with cutting-edge technology.
UT Arlington’s North Texas Genome Center (NTGC) has acquired a $1 million next-generation genetic sequencer, enhancing its ability to study genetic links between health and disease. The only instrument of its kind in North Texas, the sequencer allows for large-scale analysis of rare genetic variants, benefiting research across diverse fields from cancer biology to coral reef preservation. “This new equipment will allow our scientists to further advance their research in genomics at reduced cost,” said Kate C. Miller, UTA’s vice president for research. The upgrade will support UTA’s faculty growth initiative and strengthen interdisciplinary studies in genomics and precision medicine.
Lantern Pharma’s investigational drug LP-184, developed for treating glioblastoma (GBM), has received Fast Track designation from the FDA, expediting its review for this aggressive brain cancer affecting over 13,000 adults annually in the U.S. and around 300,000 globally. The drug, set to enter Phase 1b/2a trials for recurrent GBM in late 2024 or early 2025, could be the first new GBM treatment in over two decades. “This designation highlights LP-184’s potential to address a significant unmet need in GBM treatment,” stated Lantern Pharma CEO Panna Sharma.
Author
